BEXIMCO PHARMACEUTIC

BXPHARMA
End-of-day quote. End-of-day quote  - 01/27
198.4BDT +1.12%

Beximco Pharmaceuticals Limited Receives US Food and Drug Administration Approval for Baclofen

07/26/2021 | 02:00am
Beximco Pharmaceuticals Limited announced it has received US Food and Drug Administration (FDA) approval for Baclofen (10 and 20 mg tablets), a muscle relaxant drug indicated for the treatment of muscle pain, spasms, and stiffness in people with multiple sclerosis or spinal cord injury or disease. This is Beximco Pharma's ninth Abbreviated New Drug Application (ANDA) fully developed in-house and successfully approved for the US market since the Company's oral solid dosage facility was approved by the US FDA in June 2015. The Company expects to launch the product through its US distribution partner in due course.
© S&P Capital IQ 2022
Copier lien
All news about BEXIMCO PHARMACEUTICALS LIMITED
14h ago
14h ago
01/20
01/20
01/20